ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Cancer Advocacy: Survivors, Supporters Gather to Light Candles, Curse the Darkness

October 1, 1999

Fisher, Bonadonna Studies Still Fuel DeVita’s Optimism; Carbon Lists Six Basic Research Needs

July 15, 1977

Watson, Weinstein Decide FCRC Isn’t So Bad After all; DCCP to Develop RFAs, RFPs With Help Of Workshops

May 11, 1979

Clinical Trials Approved By NCI CTEP Last Month

May 27, 2011

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

January 27, 2012

White House Agrees To Pay Raise For NCI, NIH, NHLI Chiefs

February 27, 1976